Table 3 Results of treatment of patients with BRCA1-OC depending on the population, microscopic and clinical characteristics
From: Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer
Population, microscopic and clinical characteristics | No. of patients | 5-year overall survival | |
|---|---|---|---|
No. of patients | % | ||
The number of patients with BRCA1 gene mutation | 66 | 29 | 43.9 |
a Coexisting neoplasms | |||
- no | 57 | 28 | 49.1 |
- breast cancer | 9 | 1 | 11.1 |
a The total extent of cytoreduction | |||
- optimal | 34 | 20 | 58.8 |
- suboptimal | 32 | 9 | 28.1 |
a Staging FIGO (2009) | |||
- I | 4 | 4 | 100.0 |
- II | 8 | 5 | 62.5 |
- III | 50 | 19 | 38.0 |
- IV | 4 | 1 | 25.0 |
a Histological type | |||
- serous | 27 | 11 | 40.7 |
- endometrial | 23 | 14 | 60.9 |
- undifferentiated | 8 | 1 | 12.5 |
- mucous | 4 | 2 | 50.0 |
- clear cell | 2 | 1 | 50.0 |
- mezonefroid | 2 | 0 | 0 |
a CA125 concentration at the beginning of treatment | |||
- < 285,5 | 31 | 21 | 67.7 |
- ≥285,5 | 35 | 8 | 22.9 |
a CA125 concentration at the end of treatment | |||
- <12,5 | 34 | 22 | 64.7 |
- ≥12,5 | 22 | 7 | 31.8 |